John Sharman our CEO and the company continue to perform impressively as if this earnings guidance is met it will represent a 30% increase on last years profit. Unfortunately though this will not translate to a 30% increase in EPS due to the dividend reinvestment plan taken up by David Williams, our Chairman and major shareholder.
The major European trial currently being conducted by MVP for their main product Penthrox is set to conclude in the 1st quarter of FY13 and as this will open up large new markets in the European Union hopefully the days of 30% YOY increases in profits have just begun.
I see a huge future for this company over the next 10 years.
Ann: MVP Further Earnings Guidance , page-2
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.005(1.10%) |
Mkt cap ! $50.69M | |||
| Open | High | Low | Value | Volume |
| 45.5¢ | 45.5¢ | 45.0¢ | $46.15K | 101.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36411 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 7129 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MVP (ASX) Chart |